A Trusted Partner from Molecule to Market

Cayman is a global contract development and manufacturing organization (CDMO) that supports academic, pharma, and biotech clients across the entire drug development lifecycle, from drug discovery through clinical trials to commercialization. With over 40 years of experience, we have proven expertise in API development and manufacturing in full compliance with CGMP standards.

Support for Every Step of the Drug Development Journey

Cayman has a full range of CDMO services that are available as stand-alone services or as part of a comprehensive API discovery, development, and manufacturing program.

Meet the Team

Shannon Stacey

Vice President of CGMP Operations

Cayman Chemical

Mrs. Stacey joined Cayman Chemical’s Quality Control department in 1994. She moved up through the quality division of the company and was promoted to Vice President of Quality and Regulatory Affairs in 2004 where she was instrumental in establishing the CGMP division at Cayman. Shannon currently provides leadership and oversight to the CGMP division.

Randy Strube

Director of Business Development

Cayman Chemical

Dr. Strube joined Cayman Chemical in 2018 and in his current role works closely with preclinical discovery clients and CDMOs to bridge lead compound programs and novel APIs into investigational development and CGMP manufacturing phases. He holds his Ph.D. in Cancer Biology and has served in various management and leadership positions in sales and marketing within the life sciences sector for over 17 years.

Gilles Chambournier

Senior Director of GMP and Process Chemistry

Cayman Chemical

Dr. Chambournier joined Cayman Chemical's Process Chemistry department in 2004. He was promoted to Manager of the Process Chemistry department in 2005, Director of CGMP and Process Chemistry in 2008, and Senior Director of CGMP and Process Chemistry in 2020. He is instrumental in the development and validation of production processes of APIs for Cayman Chemical. He provides oversight and leadership for all APIs produced at Cayman Chemical.

Kaj Johansson

Manager of CGMP Quality Assurance

Cayman Chemical

Mr. Johansson joined Cayman Chemical’s Production Chemistry department as an intern in 2004. He moved up through the Production Chemistry department and was promoted to Scientist in 2016. He then joined the CGMP division in 2018 as a Quality Assurance Specialist and was promoted to CGMP Quality Assurance Manager in 2020. He provides oversight and leadership for all Quality and Regulatory aspects in relation to CGMP products manufactured at Cayman Chemical.

Carolyn Smith

Senior Project Manager

Cayman Chemical

Mrs. Smith joined Cayman Chemical as a Regulatory and Safety Manager in 2008. She moved into a Project Manager role in the CGMP division in 2012 and was promoted to Senior Project Manager in 2019. She provides direction and oversight for all client-based CGMP products manufactured at Cayman Chemical.

Petra Miketova

Managing Director

Cayman Pharma

Dr. Miketova joined Cayman Pharma’s Research and Development Unit in 2008 as Director. She was then promoted to Managing Director in 2011. She provides oversight for quality, production, sales, and development activities and leads innovation process in the company.

Barbora Filounová

Director of Quality

Cayman Pharma

Ms. Filounova joined Cayman Pharma s. r. o. in 2018 as an HPLC validation specialist. In 2022, she was promoted to QC Manager. She has a wide range of laboratory experience from various fields of industry. In 2024, she completed the course for Qualified Person. She is responsible for activities related to the Quality Assurance and Quality Control units.

Jiri Kratochvil

Commercial Director

Cayman Pharma

Dr. Kratochvil joined Cayman Pharma’s Research and Development Unit in 2016. He was then promoted to the Head of Regulatory Department and subsequently to Commercial Director. Dr. Kratochvil provides oversight for the business and regulatory agenda.

Jan Pavlík

Operations Director

Cayman Pharma

Dr. Pavlík joined Cayman Pharma’s Research and Development Unit in 2008. He was then promoted to Director and subsequently to Operations Director. Dr. Pavlík provides oversight for the production agenda.